Jocelyn Spoon, MD
Cardiovascular Disease · Missoula, MTNPI 1548427644
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $12,750 of the $16,649 with a category attached, or 76.6%. Boston Scientific accounts for 86.6% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2023 at $9,581 and has fallen 86.3% since, to $1,317 in 2025. Among cardiovascular disease clinicians in MT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 45 payments — averaging $369.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$14K
- Abbott$1K
- Edwards Lifesciences$781
- Medtronic$132
What the payments were for
- Speaking & faculty fees$12,75077%
- Travel & lodging$3,23019%
- Food & beverage$6684%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 23 | $14,410 |
| Abbott | 11 | $1,326 |
| Edwards Lifesciences | 8 | $781 |
| Medtronic | 3 | $132 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$16,649 in reported general payments places this provider in the 90th percentile of 49 cardiovascular disease providers in Montana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 27 | $27,034 |
| Repatha SureclickEvolocumab | 26 | $18,172 |
| XareltoRivaroxaban | 15 | $9,362 |
| Metoprolol Succinate | 68 | $1,281 |
| ClopidogrelClopidogrel Bisulfate | 112 | $1,206 |
| Atorvastatin Calcium | 48 | $578 |
| Carvedilol | 34 | $440 |
| Lisinopril | 45 | $436 |
| Losartan Potassium | 40 | $391 |
| Potassium Chloride | 15 | $285 |
| Amlodipine Besylate | 23 | $250 |
| Furosemide | 28 | $155 |
| Metoprolol Tartrate | 14 | $135 |
| Rosuvastatin Calcium | 21 | $113 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Missoula
- Patricia KellyMissoula$12K
- Newton CoutinhoMissoula$10K
- Michael ReedMissoula$8K
- Gregory WoodMissoula$6K
- Morgan KelloggMissoula$4K
- Ashley MaysMissoula$4K
- Matthew WeissMissoula$3K
- Puneet BansalMissoula$2K
- Alexander JehleMissoula$2K
- Jon McGregorMissoula$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.